Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

The enteric microbiome in hepatobiliary health and disease
Varghese, Cyril , O’Hara, Steven P. , Tabibian, James H. , LaRusso, Nicholas F.

Liver International | November 12, 2015 | Volume: 36 | Issue: 4 | Pages: 480-487

10.1111/liv.13009 | PMID 26561779 Get It

Abstract Increasing evidence points to the contribution of the intestinal microbiome as a potentially key determinant in the initiation and/or progression of hepatobiliary disease. While current understanding of this dynamic is incomplete, exciting insights are continually being made and more are expected given the developments in molecular and high‐throughput omics techniques. In this brief review, we provide a practical and updated synopsis of the interaction of the intestinal microbiome with the liver and its downstream impact on the initiation, progression and complications of hepatobiliary disease.
Calcium-Modulating Cyclophilin Ligand Is Essential for the Survival of Activated T Cells and for Adaptive Immunity
Chan, Siaw-Li , Lindquist, Lonn D., Hansen, Michael J. , Girtman, Megan A. , Pease, Larry R. , Bram, Richard J.

The Journal of Immunology | November 12, 2015 | Volume: 195 | Issue: 12 | Pages: 5648-5656

10.4049/jimmunol.1500308 | PMID 26561552 Get It

Abstract Calcium-modulating cyclophilin ligand (CAML) is an endoplasmic reticulum resident protein that is widely expressed. Although it has been demonstrated to participate in the tail-anchored protein insertion pathway, its physiological role in the mature immune system is unknown. In this work, we show that mature, peripheral T cells require CAML for survival specifically following TCR-induced activation. In this study, we examined mature T cells from spleen and lymph nodes of tamoxifen-inducible CAML knockout mice (tCAML−/−). Whereas CAML-deficient T cells were able to express the early activation markers CD25 and CD69, and produce IL-2 normally upon stimulation, deficient cells proliferated less and died. Cells did not require CAML for entry into the S phase of the cell cycle, thus implicating its survival function at a relatively late step in the T cell activation sequence. In addition, CAML was required for homeostatic proliferation and for Ag-dependent cell killing in vivo. These results demonstrate that CAML critically supports T cell survival and cell division downstream of T cell activation.
Neuropilin-2 Regulates Endosome Maturation and EGFR Trafficking to Support Cancer Cell Pathobiology
Dutta, Samikshan , Roy, Sohini , Polavaram, Navatha S., Stanton, Marissa J., Zhang, Heyu , Bhola, Tanvi, Hönscheid, Pia , Donohue, Terrence M. , Band, Hamid , Muders, Michael H. , Datta, Kaustubh , Batra, Surinder K.

Cancer Research | November 11, 2015 | Volume: 76 | Issue: 2 | Pages: 418-428

10.1158/0008-5472.can-15-1488 | PMID 26560516 Get It

Abstract Neuropilin-2 (NRP2) is a non-tyrosine kinase receptor frequently overexpressed in various malignancies, where it has been implicated in promoting many protumorigenic behaviors, such as imparting therapeutic resistance to metastatic cancer cells. Here, we report a novel function of NRP2 as a regulator of endocytosis, which is enhanced in cancer cells and is often associated with increased metastatic potential and drug resistance. We found that NRP2 depletion in human prostate and pancreatic cancer cells resulted in the accumulation of EEA1/Rab5-positive early endosomes concomitant with a decrease in Rab7-positive late endosomes, suggesting a delay in early-to-late endosome maturation. NRP2 depletion also impaired the endocytic transport of cell surface EGFR, arresting functionally active EGFR in endocytic vesicles that consequently led to aberrant ERK activation and cell death. Mechanistic investigations revealed that WD-repeat– and FYVE-domain–containing protein 1 (WDFY1) functioned downstream of NRP2 to promote endosome maturation, thereby influencing the endosomal trafficking of EGFR and the formation of autolysosomes responsible for the degradation of internalized cargo. Overall, our results indicate that the NRP2/WDFY1 axis is required for maintaining endocytic activity in cancer cells, which supports their oncogenic activities and confers drug resistance. Therefore, therapeutically targeting endocytosis may represent an attractive strategy to selectively target cancer cells in multiple malignancies. Cancer Res; 76(2); 418–28. ©2015 AACR.
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Yufang , Tang, Nan , Thompson, Reid C., Mobley, Bret C. , Clark, Steven W., Wang, Jialiang , Sarkaria, Jann N.

Clinical Cancer Research | November 11, 2015 | Volume: 22 | Issue: 7 | Pages: 1767-1776

10.1158/1078-0432.ccr-15-1677 | PMID 26561558 Get It

Abstract Purpose: Aberrant activation of EGFR is a hallmark of glioblastoma. However, EGFR inhibitors exhibit at best modest efficacy in glioblastoma. This is in sharp contrast with the observations in EGFR-mutant lung cancer. We examined whether activation of functionally redundant receptor tyrosine kinases (RTKs) conferred resistance to EGFR inhibitors in glioblastoma. Experimental Design: We collected a panel of patient-derived glioblastoma xenograft (PDX) lines that maintained expression of wild-type or mutant EGFR in serial xenotransplantation and tissue cultures. Using this physiologically relevant platform, we tested the abilities of several RTK ligands to protect glioblastoma cells against an EGFR inhibitor, gefitinib. Based on the screening results, we further developed a combination therapy cotargeting EGFR and insulin receptor (InsR)/insulin-like growth factor 1 receptor (IGF1R). Results: Insulin and IGF1 induced significant protection against gefitinib in the majority of EGFR-dependent PDX lines with one exception that did not express InsR or IGF1R. Blockade of the InsR/IGF1R pathway synergistically improved sensitivity to gefitinib or dacomitinib. Gefitinib alone effectively attenuated EGFR activities and the downstream MEK/ERK pathway. However, repression of AKT and induction of apoptosis required concurrent inhibition of both EGFR and InsR/IGF1R. A combination of gefitinib and OSI-906, a dual InsR/IGF1R inhibitor, was more effective than either agent alone to treat subcutaneous glioblastoma xenograft tumors. Conclusions: Our results suggest that activation of the InsR/IGF1R pathway confers resistance to EGFR inhibitors in EGFR-dependent glioblastoma through AKT regulation. Concurrent blockade of these two pathways holds promise to treat EGFR-dependent glioblastoma. Clin Cancer Res; 22(7); 1767–76. ©2015 AACR.
Use ofCandidaantigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience
Alikhan, Ali , Griffin, John R., Newman, Catherine C.

Journal of Dermatological Treatment | November 11, 2015 | Volume: 27 | Issue: 4 | Pages: 355-358

10.3109/09546634.2015.1106436 | PMID 26558635 Get It

The most effective and promising population health strategies to advance human papillomavirus vaccination
Agunwamba, Amenah A. , Sauver, Jennifer L. St. , Jacobson, Robert M. , St Sauver, Jennifer L, Finney Rutten, Lila J, Rutten, Lila J. Finney , St Sauver, Jennifer L

Expert Review of Vaccines | November 11, 2015 | Volume: 15 | Issue: 2 | Pages: 257-269

10.1586/14760584.2016.1116947 | PMID 26559567 Get It

Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas
Jiang, Wen , Chamberlain, Paul , Garden, Adam S. , Kim, Betty Y.S. , Ma, Dominic , Lo, Emily J., Bell, Diana , Gunn, G. Brandon , Fuller, Clifton D. , Rosenthal, David I. , Beadle, Beth M. , Frank, Steven J. , Morrison, William H. , Glisson, Bonnie S. , Phan, Jack , El‐Naggar, Adel K. , Sturgis, Erich M. , Jiang, Wen , Kim, Betty Y S , Phan, Jack , Fuller, Clifton David

Head & Neck | November 11, 2015 | Volume: 38 | Issue: S1 | Pages: No page available

10.1002/hed.24258 | PMID 26560893 Get It

AbstractBackgroundOverexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear.MethodsEighty‐six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein‐Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining.ResultsEBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p < .004), progression‐free survival (PFS; median, 80.4 vs 28.1 months; p < .013), and locoregional control (median, 104.4 vs 65.5 months; p < .043). In patients with EBV‐positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p < .02) and locoregional control (median, 93.6 vs 64.5 months; p < .02).ConclusionP16 overexpression is associated with improved PFS and locoregional control in patients with EBV‐positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC. © 2015 Wiley Periodicals, Inc. Head Neck 38: E1459–E1466, 2016
Preoperative platelet transfusions and perioperative red blood cell requirements in patients with thrombocytopenia undergoing noncardiac surgery
Warner, Matthew A. , Jia, Qing , Clifford, Leanne, Wilson, Gregory , Brown, Michael , Hanson, Andrew C. , Schroeder, Darrell R. , Kor, Daryl J. , Warner, Matthew A , Schroeder, Darrell

Transfusion | November 11, 2015 | Volume: 56 | Issue: 3 | Pages: 682-690

10.1111/trf.13414 | PMID 26559936 Get It

BACKGROUNDPerioperative hemorrhage impacts patient outcomes and health care resource utilization, yet the risks of transfusion therapies are significant. In patients with preoperative thrombocytopenia, the effects of prophylactic preoperative platelet (PLT) transfusion on perioperative bleeding complications remain uncertain.STUDY DESIGN AND METHODSThis is a retrospective cohort study of noncardiac surgical patients between January 1, 2008, and December 31, 2011. Propensity‐adjusted analyses were used to evaluate associations between preoperative thrombocytopenia, preoperative PLT transfusion, and the outcomes of interest, with a primary outcome of perioperative red blood cell (RBC) transfusion.RESULTSA total of 13,978 study participants were included; 860 (6.2%) had a PLT count of not more than 100 × 109/L with 71 (8.3%) receiving PLTs preoperatively. Administration of PLTs was associated with higher rates of perioperative RBC transfusion (66.2% vs. 49.1%, p = 0.0065); however, in propensity‐adjusted analysis there was no significant difference between groups (odds ratio [OR] [95% confidence interval {95% CI}], 1.68 [0.95‐2.99]; p = 0.0764]. Patients receiving PLTs had higher rates of intensive care unit (ICU) admission (OR [95% CI], 1.95 [1.10‐3.46]; p = 0.0224) and longer hospital lengths of stay (estimate [95% bootstrap CI], 7.2 [0.8‐13.9] days; p = 0.0006) in propensity‐adjusted analyses.CONCLUSIONPreoperative PLT transfusion did not attenuate RBC requirements in patients with thrombocytopenia undergoing noncardiac surgery. Moreover, preoperative PLT transfusion was associated with increased ICU admission rates and hospital duration. These findings suggest that more conservative management of preoperative thrombocytopenia may be warranted.